Search

Displaying results 2611 - 2620 of 3888 in total
  1. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    [L36105] Belzutifan inhibits the complexation of HIF-2α with another transcription factor, HIF-1β, a necessary step in its activation - by preventing the formation of this complex, belzutifan can slow

  2. Drug

    Gemeprost

    go.drugbank.com/drugs/DB08964
    ApprovedWithdrawn

    Gemeprost is a prostaglandin E1 (PGE1) analog and antiprogestogen used for preoperative dilation of the cervix before surgical abortion. It is available as vaginal suppositories and also used in combination with the antiprogestin and mif...

    Categories: Genito Urinary System and Sex Hormones
  3. Target

    NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial

    go.drugbank.com/bio_entities/BE0000305
    TargetHumans

    Required for proper complex I assembly (PubMed:28671271). Complex I functions in the transfer of electrons from NADH to the respiratory chain. … Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis.

    Synonyms: Complex I-39kD
  4. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November

  5. Drug

    Refametinib

    go.drugbank.com/drugs/DB06309
    Investigational

  6. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a ser...

    Categories: Complex Mixtures
  7. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®; Both biosimilars also received marketing authorization in the EU

    Categories: Complex Mixtures
  8. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention

  9. Target

    Nuclear factor of activated T-cells, cytoplasmic 1

    go.drugbank.com/bio_entities/BE0004878
    TargetHumans

    Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 or IL-4 gene transcription. Also controls gene expression in embryonic cardiac cells. Could regulate not only the activation a...

    Synonyms: NFAT transcription complex cytosolic component
  10. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause